<?xml version="1.0" encoding="UTF-8"?>
<p id="par0070">Randomized controlled trials were initiated and are being conducted for many antiviral agents. Lopinavir (LPV) was shown to inhibit the protease activity of coronavirus 
 <italic>in vitro</italic> and in animal models and already used for SARS and MERS in combination with ritonavir, another antiviral drug [
 <xref rid="bib0375" ref-type="bibr">75</xref>,
 <xref rid="bib0380" ref-type="bibr">76</xref>]. However, a recent trial showed lopinavir-ritonavir has no treatment benefit for severely infected patients by SARS-CoV-2 [
 <xref rid="bib0385" ref-type="bibr">77</xref>]. Ribavirin is a guanosine analogue, used to treat several viral infections including those caused by the hepatitis C and respiratory syncytial viruses by targetting the RdRp complex [
 <xref rid="bib0390" ref-type="bibr">78</xref>]. Messenger RNA (mRNA) vaccine technology is also under development (in phase 1 clinical trial by the US National Institute of Allergy and Infectious Diseases) [
 <xref rid="bib0395" ref-type="bibr">79</xref>].
</p>
